About Lexaria Bioscience Corp.
https://lexariabioscience.comLexaria Bioscience Corp. operates as a biotechnology company.
CEO
Richard C. Christopher
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public N/A
Method of going public SPAC
Full time employees 7
Ratings Snapshot
Rating : C+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 4
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $137061
52w High $0.03
52w Low $0.00
P/E 0
Volume 58.22K
Outstanding Shares 22.11M
About Lexaria Bioscience Corp.
https://lexariabioscience.comLexaria Bioscience Corp. operates as a biotechnology company.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $174K | $3.92M ▲ | $-3.79M ▼ | -2.18K% ▼ | $-0.21 ▼ | $-3.72M ▼ |
| Q2-2025 | $174K ▼ | $2.93M ▲ | $-2.71M ▼ | -1.56K% ▼ | $-0.15 ▲ | $-2.75M ▼ |
| Q1-2025 | $183.92K ▲ | $2.87M ▲ | $-2.7M ▼ | -1.47K% ▲ | $-0.16 ▲ | $-2.66M ▼ |
| Q4-2024 | $84K | $2.29M ▲ | $-2.18M ▼ | -2.6K% ▼ | $-0.17 ▼ | $-2.2M ▼ |
| Q3-2024 | $84K | $1.83M | $-1.78M | -2.12K% | $-0.13 | $-1.73M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.63M ▼ | $6.74M ▼ | $1.57M ▼ | $5.55M ▼ |
| Q2-2025 | $6.54M ▼ | $8.68M ▼ | $1.92M ▲ | $7.14M ▼ |
| Q1-2025 | $8.12M ▲ | $9.79M ▲ | $399.72K ▼ | $9.77M ▲ |
| Q4-2024 | $6.56M ▼ | $8.87M ▼ | $1.21M ▲ | $8.04M ▼ |
| Q3-2024 | $8.51M | $10.02M | $271.38K | $10.12M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.79M ▼ | $-3.58M ▼ | $-19.44K ▲ | $1.69M ▲ | $-1.88M ▼ | $-3.58M ▼ |
| Q2-2025 | $-2.72M ▼ | $-1.5M ▲ | $-27.89K ▲ | $11.72K ▼ | $-1.61M ▼ | $-1.5M ▲ |
| Q1-2025 | $-2.71M ▼ | $-2.73M ▼ | $-37.8K ▲ | $4.35M ▲ | $1.58M ▲ | $-2.73M ▼ |
| Q4-2024 | $-2.19M ▼ | $-1.89M ▼ | $-69.59K ▼ | $0 ▼ | $-1.96M ▼ | $-1.96M ▼ |
| Q3-2024 | $-1.78M | $-1.27M | $-22K | $5.04M | $3.75M | $-1.29M |
Revenue by Products
| Product | Q3-2024 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
 B2B | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 IP Licensing | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Richard C. Christopher
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public N/A
Method of going public SPAC
Full time employees 7
Ratings Snapshot
Rating : C+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 4
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0